Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics

Key Points

• GLP-1 receptor agonists significantly enhance weight management and appetite control in patients with obesity.
• A meta-analysis of multiple trials reveals a reduction of up to 10% in body weight with GLP-1 therapies.
• Observational analysis focused on pharmacotherapy interventions in managing obesity-related metabolic pathways.
• These findings support the potential of GLP-1 receptor agonists as a key therapeutic strategy for obesity treatment.